CION Ameerpet
Immunotherapy Side Effects · Heart, Kidney, Muscle & Nerve Reactions
Muscle Weakness and Myositis on Immunotherapy — What It Feels Like and Why It's Urgent
Immune myositis is a rare inflammation of the muscles caused by an overactive immune response during checkpoint-inhibitor immunotherapy. It affects only a small proportion of patients, but it can overlap with immune myocarditis and myasthenia-type nerve weakness — a combination worth naming and taking seriously. NCCN and ASCO guidance on immune-related adverse events treats new or spreading muscle weakness during immunotherapy as an urgent, same-day evaluation, not a symptom to watch and wait on.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Rare, but can move fast — myositis affects only a small proportion of patients, but can worsen within days once it starts.
- A dangerous triad — myositis can overlap with immune myocarditis (heart) and myasthenia-type weakness (nerve).
- Easy to miss — mild weakness climbing stairs or lifting the arms is often mistaken for ordinary tiredness.
- Go to the ER for red flags — breathlessness, swallowing trouble, drooping eyelids or chest symptoms need emergency care immediately.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Symptom triage
How Urgent Is Muscle Weakness or Myositis on Immunotherapy?
New or spreading muscle weakness during immunotherapy is always worth same-day medical attention, because immune myositis can overlap with immune myocarditis and myasthenia-type nerve weakness — a combination that can affect breathing or the heart within days. Any weakness that stops you climbing stairs, lifting your arms, or gets rapidly worse needs prompt evaluation, not a wait-and-see approach.
Go to the ER now, or call an ambulance, if you have muscle weakness together with any of these:
- Breathlessness, or difficulty taking a full breath
- Difficulty swallowing, or a change in your voice
- Drooping eyelids or double vision
- Chest pain, palpitations, or an irregular heartbeat
For any other new or worsening muscle weakness during immunotherapy, call the CION helpline the same day:
Call the CION Helpline Now: 1800 202 8726
Know the difference
What Does Immune Myositis Feel Like?
Immune myositis usually feels like new, unusual weakness rather than ordinary tiredness — difficulty climbing stairs, lifting the arms overhead, standing up from a low chair, or a heavy, aching feeling in the thighs and shoulders. Some patients also notice muscle tenderness, neck weakness, or trouble swallowing. Because it can appear alongside a heart or nerve reaction, any new weakness pattern during immunotherapy is checked with a blood muscle-enzyme (CK) test rather than assumed to be treatment fatigue.
| Feature | Everyday tiredness (exertion, poor sleep, low mood) | Possible immune myositis — needs prompt review |
|---|---|---|
| Pattern | General low energy, not tied to specific muscles | Weakness concentrated in shoulders, upper arms, hips and thighs, often on both sides |
| Onset | Comes on gradually, fluctuates day to day | New or worsening over days, sometimes rapidly |
| Response to rest | Improves with rest and sleep | Little or no improvement with rest |
| Associated signs | None specific | Muscle tenderness, swallowing difficulty, voice change, or drooping eyelids |
| Everyday tasks | Manageable, if slower | Newly unable to climb stairs, lift arms overhead, or rise from a chair without using hands |
Timing matters
How Soon After Starting Immunotherapy Does Myositis Appear?
Immune myositis most often develops within the first few cycles of checkpoint-inhibitor immunotherapy — commonly the first six to twelve weeks — though it can occur at any point during treatment. Because it can arrive alongside myocarditis or myasthenia-type weakness, any new muscle symptom in the early cycles is reported the same day it appears, not tracked for a few days to see if it settles.
| Stage | What's typically happening |
|---|---|
| Typically starts | Most often within the first few cycles (roughly the first 6–12 weeks) of checkpoint-inhibitor immunotherapy — though it can occur at any point, including later in treatment. |
| Early phase | Mild weakness climbing stairs or lifting the arms, muscle aching, or tenderness — easy to mistake for general treatment tiredness. |
| If unreported | Can progress to more widespread weakness, swallowing or breathing difficulty, or spread to involve the heart or nerve conduction, within days. |
There is no safe home-management step for new muscle weakness that comes with breathlessness, swallowing difficulty, drooping eyelids or chest symptoms during immunotherapy. Because myositis, myocarditis and myasthenia-type weakness can occur together, the correct response is always the same: get it checked immediately, or go to the ER for the emergency signs above.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Don't Wait Out New Muscle Weakness on Immunotherapy
Our tumour board includes the same specialists managing your immunotherapy — reach them directly.
What comes after you call
How Immune Myositis Is Diagnosed and Treated
Reporting new muscle weakness early leads to a structured assessment, not guesswork — the heart and nerve pathways are checked alongside the muscles, and treatment starts promptly once myositis is confirmed.
- 1
Blood muscle-enzyme (CK) test
A blood test measuring creatine kinase and related muscle-injury markers is usually the first step, alongside a basic examination of muscle strength.
- 2
Heart and nerve screening
Because myositis can overlap with immune myocarditis and myasthenia-type weakness, an ECG, troponin blood test, and a check for swallowing, breathing or eyelid involvement are done at the same visit.
- 3
Specialist referral
A neurologist and, if the heart screen raises any concern, a cardiologist are brought in alongside your oncology team — this is managed jointly, not by oncology alone.
- 4
High-dose steroids
Treatment usually starts with high-dose steroids; more severe or overlapping cases may need additional immune-suppressing medication under close monitoring.
- 5
Decision on immunotherapy
Depending on severity and whether the heart or nerves are also affected, your tumour board decides whether immunotherapy can continue, needs a pause, or should be stopped for that patient.
Care during treatment
Rare Reactions Are Manageable When Caught Early
Patients who report new muscle weakness immediately are supported by the same multidisciplinary team throughout treatment.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Muscle Weakness and Myositis: Your Questions Answered
What does immune myositis feel like?
Immune myositis usually feels like new, unusual weakness rather than ordinary tiredness — difficulty climbing stairs, lifting the arms overhead, standing up from a low chair, or a heavy, aching feeling in the thighs and shoulders. Some patients also notice muscle tenderness, neck weakness, or trouble swallowing. Because it can appear alongside immune myocarditis or myasthenia-type weakness, any new weakness pattern during immunotherapy is checked with a blood muscle-enzyme test rather than assumed to be treatment fatigue.
Why is muscle weakness during immunotherapy urgent?
Immune myositis is rare, but it can overlap with immune myocarditis (a heart reaction) and myasthenia-type neuromuscular weakness — together sometimes called a dangerous triad — and can progress to breathing difficulty or heart involvement within days. NCCN and ASCO guidance on immune-related adverse events treats new or spreading muscle weakness during immunotherapy as an urgent, same-day evaluation, not a symptom to monitor at home.
How is immune myositis different from ordinary weakness or fatigue?
Ordinary treatment fatigue tends to improve with rest and affects overall energy rather than specific muscle groups. Immune myositis typically causes progressive, often symmetric weakness in the muscles closest to the body — shoulders, upper arms, hips and thighs — that does not improve with rest and can worsen over days. Warning signs that point away from ordinary fatigue include difficulty swallowing, a change in your voice, drooping eyelids, breathlessness, or dark-coloured urine.
Can myositis occur together with a heart or nerve reaction?
Yes. Immune myositis, immune myocarditis and myasthenia-type neuromuscular weakness can occur together in the same patient, which is why any new muscle weakness during immunotherapy prompts a check of heart function (ECG and troponin) and neuromuscular signs such as drooping eyelids, double vision or breathing difficulty, alongside the muscle-enzyme blood test.
What should I do if I notice new muscle weakness on immunotherapy?
Call the CION helpline the same day you notice new or worsening muscle weakness during immunotherapy — do not wait to see if it settles. Go to the nearest emergency room immediately if the weakness comes with breathlessness, difficulty swallowing, chest pain, palpitations, drooping eyelids or double vision, since these can point to the heart or nerve reactions that sometimes accompany myositis.
How is immune myositis treated?
Treatment usually starts with blood tests to measure muscle-enzyme levels and a check for heart and neuromuscular involvement, followed by high-dose steroids under specialist supervision. More severe cases may need additional immune-suppressing treatment and input from a neurologist or cardiologist. Depending on severity, your tumour board decides whether immunotherapy can continue, needs a pause, or should be stopped for that patient.